Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $935.23M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.21M
Average 0.31M
Returns on capital
Silence Therapeutics plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-142.2%
avg -142.2%
ROIC
-76.1%
avg -42.6%
ROA
-67.4%
avg -33.4%
Analysis
ROA is currently the strongest return metric at -67.4% versus its period average of -33.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Steven J. Romano | Executive Vice President and Chief Research & Development Officer | GBP 496.67K | 67 | 300.00K | 0.64% |
Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | GBP 188.86K | 55 | — | — |
Iain Gladstone Ross | Interim CEO & Chairman of the Board | GBP 131.26K | 72 | — | — |
Marie Wikstrom Lindholm | Chief Scientific Officer | — | — | — | — |
Curtis Rambaran | Chief Medical Officer | — | — | — | — |
Jaimin Shah | SVP & General Counsel | — | — | — | — |
Gabriel | Chief Technical Operations Officer | — | — | — | — |
Gem Gokmen Hopkins | VP and Head of IR & Corporate Communications | — | — | — | — |
Marianna Anesti | VP & Head of Business Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$104.14M
Sells
0
$0.00
Net Transaction Value
+$104.14M
Net buying
Most Active
Griffiths Richard Ian
17 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $1.6M$1,558,000.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $44.7M$44,685,216.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $804.5K$804,500.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $57.2K$57,225.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $12.8M$12,800,000.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $6.1M$6,112,000.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $7.6M$7,575,493.80 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $9.7M$9,682,784.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $1.9M$1,920,000.00 |
| Aug 10, 26Aug 10, 2026 | Griffiths Richard Ian Indirect | Buy | $981K$981,000.00 |
1–10 of 17
Summary
Insiders reported 17 buys worth $104.14M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $104.14M. Griffiths Richard Ian was the most active insider with 17 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -68.4% | +213.7% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -68.4% over three years. Forward estimates point to Revenue at +213.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Silence Therapeutics plc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SLN's management, answered from reported figures.
Who manages SLN?
Silence Therapeutics plc (SLN) lists 9 active executives. The top listed executive is Marie Wikstrom Lindholm, Chief Scientific Officer.
Are SLN insiders buying or selling?
Recent insider activity shows net buying of $124.31M.
Continue the stock analysis
Jump to another research area for this company.